TY - JOUR
T1 - COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
AU - Busca, Alessandro
AU - Salmanton-García, Jon
AU - Corradini, Paolo
AU - Marchesi, Francesco
AU - Cabirta, Alba
AU - Di Blasi, Roberta
AU - Dulery, Remy
AU - Lamure, Sylvain
AU - Farina, Francesca
AU - Weinbergerová, Barbora
AU - Batinić, Josip
AU - Nordlander, Anna
AU - López-García, Alberto
AU - Drgoňa, Ľuboš
AU - Espigado-Tocino, Ildefonso
AU - Falces-Romero, Iker
AU - García-Sanz, Ramón
AU - García-Vidal, Carolina
AU - Guidetti, Anna
AU - Khanna, Nina
AU - Kulasekararaj, Austin
AU - Maertens, Johan
AU - Hoenigl, Martin
AU - Klimko, Nikolai
AU - Koehler, Philipp
AU - Pagliuca, Antonio
AU - Passamonti, Francesco
AU - Cornely, Oliver A
AU - Pagano, Livio
PY - 2022
Y1 - 2022
N2 - The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.\r\n\r\nPrevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
AB - The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.\r\n\r\nPrevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
KW - Chimeric Antigen
KW - Receptors
KW - Chimeric Antigen
KW - Receptors
UR - https://publicatt.unicatt.it/handle/10807/217384
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85125930718&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85125930718&origin=inward
U2 - 10.1182/bloodadvances.2021005616
DO - 10.1182/bloodadvances.2021005616
M3 - Article
SN - 2473-9529
VL - 6
SP - 2427
EP - 2433
JO - Blood advances
JF - Blood advances
IS - 7
ER -